Dr. Clementi holds a patent for deep lung alveolar aerosol targeted drug delivery and other provisional patents.
BRYN MAWR, PA, August 29, 2024 /24-7PressRelease/ -- Dr. William A. Clementi has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected based on current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are considered during selection.
Dr. Clementi, an esteemed pharmaceutical professional with over five decades of experience in pharmacology and drug development, has made significant contributions to the healthcare sector. As president of Clementi and Associates Ltd. for more than 30 years, he has overseen or been involved in advancing numerous projects, over 100 single and combination products for over 50 different global companies, including most recently, regulatory guidance to the neurodegenerative disease program at the Ann Romney Center, Boston MA. His work involves the management of therapeutic approaches for biologics, drugs, and devices involving innate immunity, leading to reduced brain inflammation. Still, he skillfully uses new product development principles when interfacing with the FDA. Dr. Clementi supervised a team of qualified experts in GMP quality control systems for medical devices, biologics, and a novel excipient in other broader capacities. His career has focused on cellular and organ transplant therapy for allographic and xenographic transplantation, starting with hemoglobin-based oxygen carriers under companies funded by D. Judelson, former Chairman and Founder of Gulf and Western Corporation. He has also been instrumental in Honeywell's green gases projects and the manufacturing of propellants at a large scale for the use of metered dose inhalers such as those used in asthma. He has worked closely with senior management at Biopure, Ontogeny, Abbott, Boots, Sanofi, Pharmacia, PhotoCure, and Cook Imaging. He has published over 75 peer-reviewed clinical pharmacology and precision medicine papers, including dose individualization.
In addition to his role as President of Clementi and Associates Ltd, Dr. Clementi has concurrently served as Chief Development Officer at Tiziana Life Sciences and Chief Operating Officer at OKYO Pharma since 2023. He has now turned his focus solely to Tiziana Life Sciences. He was Director of Market Development for Lorex Pharmaceuticals-Synthelabo-Pfizer collaborations from 1984 to 1989. Three products received FDA approval, including betaxolol (Kerlone), Zolpidem (Ambien), and Alfuzosin (Uroxatrol). Before he engaged a career in the pharmaceutical industry, Dr. Clementi held multiple academic positions, including Director of the Pharmacokinetic Consultant Service at The University of Texas at Austin from 1981 to 1985, Assistant Professor (tenure track) of Pharmacology at UT Health San Antonio from 1980 to 1984, and Instructor at UT Austin from 1978 to 1979. He also directed the first Therapeutic Drug Monitoring (TDM) outpatient clinic-based service at UT Health Science Center affiliated with the Audie Murphy VA Hospital in San Antonio from 1979 to 1985. TDM clinic allowed timely post-discharge medication adjustments in patients requiring cardiac care and anticoagulation. It is believed to be the first TDM clinic in the United States.
His expertise in drug interactions and metabolism is widely recognized. Dr. Clementi holds a patent for deep lung alveolar aerosol targeted drug delivery and other provisional patents. He has mentored 13 doctoral students throughout his career. His professional affiliations include membership in the American College of Clinical Pharmacology and formerly the American Society of Clinical Pharmacology and Therapeutics.
One of Dr. Clementi's many notable achievements includes implementing an early access program for secondary progressive multiple sclerosis over the past two years, assisting 10 patients alongside Dr. H. L. Weiner at Brigham Woman's Hospital. This accomplishment is a testament to his dedication to improving patient care.
His educational background laid a strong foundation for his illustrious career. Dr. Clementi earned a Bachelor of Arts in Biology from Boston University in 1970 and a Doctor of Pharmacy from UT Health San Antonio in 1977. His doctoral thesis examined lithium-sodium ion exchange, simultaneously assessing membrane and cellular transport kinetics at the gut and kidney. His NIH-sponsored training fellowship focused on hydralazine-like vasodilators, specifically drug metabolism, and the modeling of their effects on hemodynamics. He is certified by the National Association of Boards of Pharmacy in the State of Texas and the Commonwealth of Pennsylvania. He attributes much of his success to his grandmother, who was severely handicapped and raised him, inspiring his commitment to health care.
Dr. Clementi's civic involvement includes consulting activities with the ethics committee at Delaware County Memorial Hospital from 1994 to 1999 and regulatory consulting for the QED Program at the University of Pennsylvania from 2011 to 2019. He received a VA Merit Review Grant and contributed to numerous nonlinear mixed effect modeling publications. Dr. Clementi has worked with nearly every Center at FDA, including CDER, CBER, CDRH, and the Center for Veterinary Medicine, again using early access progress for canine and feline access to development products with substantial evidence of effectiveness.
Outside his professional life, Dr. Clementi is a committed audiophile, preferring original analogue productions of composer JS Bach played on a Steinway piano and an essential collection of American and Canadian Expressionistic art. Looking ahead, he believes in product translational efforts leading to commercialization. In short, Dr. Clementi strongly believes in translational initiatives and precision medicine using pharmacologic principles to guide dosing when advancing innovation to commercialization and widespread commercial use.
About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. The suite of Marquis® publications can be viewed at the official Marquis Who's Who® website, www.marquiswhoswho.com.
# # #